SG11201907938RA - Pentosan Polysulfate, Pharmaceutical Composition, And Anticoagulant - Google Patents

Pentosan Polysulfate, Pharmaceutical Composition, And Anticoagulant

Info

Publication number
SG11201907938RA
SG11201907938RA SG11201907938RA SG11201907938RA SG11201907938RA SG 11201907938R A SG11201907938R A SG 11201907938RA SG 11201907938R A SG11201907938R A SG 11201907938RA SG 11201907938R A SG11201907938R A SG 11201907938RA SG 11201907938R A SG11201907938R A SG 11201907938RA
Authority
SG
Singapore
Prior art keywords
anticoagulant
pharmaceutical composition
pentosan polysulfate
polysulfate
pentosan
Prior art date
Application number
SG11201907938RA
Inventor
Kotaro Ishikawa
Takuro Kashiwamura
Takuya Kato
Toru Koga
Suguru Ishikawa
Original Assignee
Oji Holdings Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oji Holdings Corp filed Critical Oji Holdings Corp
Publication of SG11201907938RA publication Critical patent/SG11201907938RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0057—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Xylans, i.e. xylosaccharide, e.g. arabinoxylan, arabinofuronan, pentosans; (beta-1,3)(beta-1,4)-D-Xylans, e.g. rhodymenans; Hemicellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
    • A61L33/06—Use of macromolecular materials
    • A61L33/08—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/14—Hemicellulose; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/14—Hemicellulose; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L97/00—Compositions of lignin-containing materials
    • C08L97/02—Lignocellulosic material, e.g. wood, straw or bagasse

Abstract

504"/10-:46-'"5& 1)"3."$&65*$"-$0.104*5*0/ "/%"/5*$0"(6-"/5 </PTVJUBCMFGJHVSF> 5 10 15 20 25 30
SG11201907938RA 2017-02-28 2018-02-27 Pentosan Polysulfate, Pharmaceutical Composition, And Anticoagulant SG11201907938RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017035916 2017-02-28
JP2017166559A JP6281659B1 (en) 2017-02-28 2017-08-31 Polysulfate pentosan, pharmaceutical composition and anticoagulant
PCT/JP2018/007138 WO2018159580A1 (en) 2017-02-28 2018-02-27 Pentosan polysulfate, pharmaceutical composition and anticoagulant

Publications (1)

Publication Number Publication Date
SG11201907938RA true SG11201907938RA (en) 2019-09-27

Family

ID=61231477

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201907938RA SG11201907938RA (en) 2017-02-28 2018-02-27 Pentosan Polysulfate, Pharmaceutical Composition, And Anticoagulant

Country Status (15)

Country Link
US (1) US11274165B2 (en)
EP (1) EP3590971B1 (en)
JP (1) JP6281659B1 (en)
KR (1) KR102520754B1 (en)
CN (1) CN110325553B (en)
AU (1) AU2018229054B2 (en)
BR (1) BR112019017527B1 (en)
CA (1) CA3054533A1 (en)
ES (1) ES2929538T3 (en)
HU (1) HUE060518T2 (en)
MX (1) MX2019010189A (en)
PL (1) PL3590971T3 (en)
PT (1) PT3590971T (en)
SG (1) SG11201907938RA (en)
WO (1) WO2018159580A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6225321B1 (en) 2016-08-31 2017-11-08 王子ホールディングス株式会社 Method for producing polysulfate pentosan
WO2018043667A1 (en) * 2016-08-31 2018-03-08 王子ホールディングス株式会社 Production method for acidic xylooligosaccharide, and acidic xylooligosaccharide
JP6281659B1 (en) * 2017-02-28 2018-02-21 王子ホールディングス株式会社 Polysulfate pentosan, pharmaceutical composition and anticoagulant
SG10201913607WA (en) 2017-05-31 2020-03-30 Oji Holdings Corp Moisturizing topical preparation
CA3075485A1 (en) 2017-09-12 2019-03-21 Oji Holdings Corporation Pentosan polysulfate and method for producing pentosan polysulfate
WO2019124363A1 (en) 2017-12-20 2019-06-27 王子ホールディングス株式会社 Pentosan polysulfate and medicine containing pentosan polysulfate
AU2018437600B2 (en) * 2018-08-20 2022-11-17 Reqmed Company, Ltd. Novel pentosan polysulfate sodium preparation

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4843100B1 (en) * 1969-09-05 1973-12-17
JPS4843100A (en) * 1971-09-30 1973-06-22
US4168742A (en) 1978-03-27 1979-09-25 Hudson Products Corporation Tube bundle
FR2538404B1 (en) 1982-12-28 1985-08-23 Anic Spa
FR2543145B1 (en) 1983-03-24 1986-10-17 Sanofi Sa NOVEL XYLAN SULPHATES, THEIR PREPARATION PROCESS AND THEIR ANTI-THROMBOTIC AND HYPOLIPEMIC ACTIVITY
JPS60112708A (en) 1983-11-24 1985-06-19 Maruho Kk Humectant for skin
FR2572731B1 (en) 1984-11-07 1987-03-06 Sanofi Sa NOVEL LOW MOLECULAR WEIGHT XYLAN SULPHATES, PROCESS FOR THEIR PREPARATION AND ORAL ANTITHROMBOTIC AND HYDROPHOLIC ACTIVITY
JPS61130302A (en) 1984-11-30 1986-06-18 Tokyo Univ Ribofuranan sulfate having anticoagulant activity and its production
JPS61130301A (en) 1984-11-30 1986-06-18 Tokyo Univ Xylofuranan sulfate having anticoagulant activity and its production
US5672334A (en) 1991-01-16 1997-09-30 Access Pharmaceuticals, Inc. Invivo agents comprising cationic metal chelators with acidic saccharides and glycosaminoglycans
FR2645745B1 (en) 1989-04-12 1991-09-27 Anben Ste Civile THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF SNORING
DE3917982A1 (en) 1989-06-02 1990-12-06 Behringwerke Ag USE OF XYLANPOLYHYDROGENSULFATES FOR THE THERAPY OF CELL PROBLEMATION-RELATED DISEASES
FR2648463B1 (en) 1989-06-14 1993-01-22 Inst Fs Rech Expl Mer SULPHATE POLYSACCHARIDES, ANTICOAGULATING AGENT AND ANTI-COMPLEMENTARY AGENT OBTAINED FROM BROWN ALGAE FUCANES AND PROCESS FOR OBTAINING SAME
CA2081340A1 (en) 1990-04-26 1991-10-27 R. Martin Emanuele Composition and method for topical treatment of damaged or diseased tissue
US20010005720A1 (en) 1995-06-07 2001-06-28 U.S.A. As Represented By The Secretary Department Of Health And Human Services Method of treating chronic progressive vascular scarring diseases
DE19632840A1 (en) 1996-08-14 1998-02-19 Landsberger Albert Composition containing vitamin A
JPH10195107A (en) 1997-01-10 1998-07-28 Shiseido Co Ltd Sulfated oligohyaluronic acid
JP4336905B2 (en) 1997-12-19 2009-09-30 マルホ株式会社 Skin moisturizing emulsion lotion containing sulfated polysaccharide
US6593310B1 (en) * 2000-11-21 2003-07-15 Arthropharm Pty. Ltd. Treatment of osteoporosis
DE10141106A1 (en) 2001-08-22 2003-03-13 Aventis Pharma Gmbh Use of heparinoid derivatives for the treatment and diagnosis of heparinoid-treatable diseases
JP4073661B2 (en) 2001-12-20 2008-04-09 王子製紙株式会社 Method for producing acidic xylooligosaccharide composition
JP3772749B2 (en) 2002-01-25 2006-05-10 王子製紙株式会社 Melanin production inhibitor
JP2003221339A (en) 2002-01-29 2003-08-05 Oji Paper Co Ltd Anti-inflammatory agent
ITMI20031618A1 (en) 2003-08-06 2005-02-07 Inalco Spa POLYSACCHARIDE DERIVATIVES EQUIPPED WITH HIGH ACTIVITY
AU2005249465B2 (en) 2004-05-27 2007-12-06 Takeda Pharmaceutical Company Limited Methods for treating bleeding disorders using sulfated polysaccharides
UA87154C2 (en) 2004-08-05 2009-06-25 Івакс Драг Рісерч Інстітьют Лтд. Polysulfated glycosides and salts thereof
US20060194759A1 (en) 2005-02-25 2006-08-31 Eidelson Stewart G Topical compositions and methods for treating pain and inflammation
EP1906975A4 (en) 2005-07-22 2010-10-06 Trf Pharma Inc Method for treating sickle cell disease and sickle cell disease sequelae
CA2648578A1 (en) 2006-04-03 2007-11-01 Nutramax Laboratories, Inc. Stabilized pentosan polysulfate (pps) formulations and methods of analyzing them
GB0610350D0 (en) 2006-05-25 2006-07-05 Univ Liverpool prevention and/or treatment of neuodegenerative disorders
EP2116224B1 (en) 2006-11-27 2016-01-27 JNC Corporation Cosmetic composition
WO2008107906A1 (en) 2007-03-06 2008-09-12 Alembic Limited Process for the preparation of pentosan polysulfate or salts thereof
FI121811B (en) * 2007-06-01 2011-04-29 Upm Kymmene Corp New dispersions and processes for their preparation
HUP0900072A2 (en) 2009-02-06 2010-09-28 Egis Gyogyszergyar Nyilvanosan Transdermal pharmaceutical compositions
WO2009087581A1 (en) * 2008-01-04 2009-07-16 Alembic Limited An improved process for the preparation of pentosan polysulfate or salts thereof
JP2009196915A (en) 2008-02-20 2009-09-03 Ezaki Glico Co Ltd Composition for cosmetic
AU2008100730B4 (en) 2008-07-04 2008-10-02 Parnell Technologies Pty Ltd Sulfated polysaccharide compound for clinical use and the preparation thereof
FR2935386B1 (en) 2008-08-26 2010-09-10 Sanofi Aventis NOVEL POLYSACCHARIDES WITH ANTITHROMBOTIC ACTIVITY COMPRISING A COVALENT LIAISON WITH AN AMINO CHAIN
NZ594854A (en) 2009-02-02 2013-03-28 Otsuka Pharma Co Ltd Low-molecular polysulfated hyaluronic acid derivative and medicine containing same
CN102061323B (en) 2010-11-10 2013-09-25 山东龙力生物科技股份有限公司 Comprehensive utilization process of wood cellulose
WO2012101544A1 (en) 2011-01-29 2012-08-02 Alembic Pharmaceuticals Limited An improved process for the preparation of pentosan polysulfate or salts thereof
WO2012114349A1 (en) 2011-02-23 2012-08-30 Cadila Healthcare Limited An improved process for the preparation of pentosan polysulfate sodium
CN102766225B (en) * 2011-05-06 2015-08-05 上海医药工业研究院 A kind of piperylene gathers the preparation method of sodium sulfate and a kind of oligomeric xylose
WO2013186857A1 (en) 2012-06-12 2013-12-19 株式会社リボミック Aptamer to fgf2 and use thereof
ITMI20130112A1 (en) 2013-01-24 2014-07-25 Chemi Spa QUALIFICATION METHOD OF PENTOSAN POLYPHOSPHATE PREPARATIONS, ITS RAW MATERIALS AND PRODUCTION PROCESSES
JO3529B1 (en) 2013-02-08 2020-07-05 Amgen Res Munich Gmbh Anti-leukocyte adhesion for the mitigation of potential adverse events caused by CD3-specific binding domains
JP6132302B2 (en) 2013-05-28 2017-05-24 リーディアント・バイオサイエンシーズ・ソシエタ・アノニマＬｅａｄｉａｎｔ Ｂｉｏｓｃｉｅｎｃｅｓ Ｓ．Ａ． Derivatives of partially desulfated glycosaminoglycans as heparanase inhibitors with anti-angiogenic activity and no anticoagulant effect
CN103320548A (en) 2013-06-24 2013-09-25 稼禾生物股份有限公司 Method for preparing xylooligosaccharide and cellulose by using crop straws
JP6403317B2 (en) 2013-07-19 2018-10-10 学校法人慶應義塾 Antitumor agent
ES2907126T3 (en) * 2015-05-20 2022-04-22 Chemi Spa Process for the preparation of polysaccharides
CA2986902A1 (en) 2015-05-27 2016-12-01 Vanguard Therapeutics, Inc. Pentosan polysulfate sodium for the treatment of sickle cell disease
CN106832020A (en) 2015-12-04 2017-06-13 长春工业大学 A kind of preparation technology of maize straw Pentosan sulphate
CN105907896B (en) 2016-05-16 2019-11-12 中国科学院广州能源研究所 A method of utilizing lignocellulose raw material coproduction high concentration xylose and xylo-oligosaccharide
JP6225321B1 (en) 2016-08-31 2017-11-08 王子ホールディングス株式会社 Method for producing polysulfate pentosan
WO2018043667A1 (en) * 2016-08-31 2018-03-08 王子ホールディングス株式会社 Production method for acidic xylooligosaccharide, and acidic xylooligosaccharide
JP6281659B1 (en) * 2017-02-28 2018-02-21 王子ホールディングス株式会社 Polysulfate pentosan, pharmaceutical composition and anticoagulant

Also Published As

Publication number Publication date
ES2929538T3 (en) 2022-11-30
WO2018159580A1 (en) 2018-09-07
PL3590971T3 (en) 2023-01-23
CN110325553B (en) 2021-10-08
CA3054533A1 (en) 2018-09-07
AU2018229054A1 (en) 2019-09-12
CN110325553A (en) 2019-10-11
PT3590971T (en) 2022-11-29
MX2019010189A (en) 2019-10-09
BR112019017527A2 (en) 2020-03-31
JP2018141120A (en) 2018-09-13
US11274165B2 (en) 2022-03-15
BR112019017527B1 (en) 2024-03-12
KR20190120216A (en) 2019-10-23
HUE060518T2 (en) 2023-03-28
US20200062867A1 (en) 2020-02-27
JP6281659B1 (en) 2018-02-21
EP3590971B1 (en) 2022-10-12
AU2018229054B2 (en) 2021-09-16
EP3590971A4 (en) 2020-12-09
KR102520754B1 (en) 2023-04-11
EP3590971A1 (en) 2020-01-08

Similar Documents

Publication Publication Date Title
SG11201907938RA (en) Pentosan Polysulfate, Pharmaceutical Composition, And Anticoagulant
PH12020500396A1 (en) Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
MX2019009839A (en) Functionalized erythroid cells.
MX2018015699A (en) Cannabinoid formulations.
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
PH12017501342A1 (en) Glycan therapeutics and related methods thereof
MX2019000427A (en) Self-emulsifying compositions of cannabinoids.
GEP20207158B (en) Amide-substituted pyridinyltriazole derivatives and uses thereof
MX2018006217A (en) Apelin receptor agonists and methods of use.
MY191581A (en) Anti-pd-1 antibodies
AU2017228405A8 (en) Small molecule IRE1-alpha inhibitors
SA518400356B1 (en) Arginase inhibitors and their therapeutic applications
PH12019502676A1 (en) Moisturizing topical preparation
MX2018015272A (en) Anti-cd98 antibodies and antibody drug conjugates.
MX2019007641A (en) Antibody drug conjugates (adcs) having enzymatically cleavable groups.
PH12020551716A1 (en) Anti-ror antibody constructs
MX2018015268A (en) Anti-cd98 antibodies and antibody drug conjugates.
MX2019001121A (en) New cannabis tablet formulations and compositions and methods of making the same.
MX2018015274A (en) Anti-cd98 antibodies and antibody drug conjugates.
MX2018012618A (en) Oral pharmaceutical compositions of mesalazine.
MX2020012800A (en) Cannabinoids and uses thereof.
MX2020011756A (en) Pharmaceutical compound, salts thereof, formulations thereof, and methods of making and using same.
PH12018501758A1 (en) Oritavancin formulations
TW201613861A (en) Sugar derivatives comprising sulfur-containing moieties and methods of making same and methods of using the same for the treatment of MPS IIIC